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One of the impressive things that the current 
Council has succeeded in doing is ensuring the 
regular and timely release of our Newsletter 
CONNECT and this resonates with my own 
efforts to ensure the regular release of the 
AOFOG Newsletter.  Anyone involved in this 
endeavour will readily attest to the challenges 
involved and my heartiest congratulations to Dr 
Eeson and his team on a magnificent effort. As 
the name suggests, the Newsletter is a lifeline to 
connect and communicate with the membership 
at large. It also shows that the OGSM is alive and 
kicking and the myriad of activities carried out 
over this term certainly attests to this.
But are we content to be just “alive and kicking”?
Through my involvement with AOFOG, I have 
had the good fortune of seeing up close the 
workings of many national O&G organisations 
and believe you me, I have seen the “good, the 
bad and the ugly”. OGSM has certainly achieved 
a good level but we have the potential to reach 
greater heights.
As we approach the 6th decade of our existence, 
a great many changes have taken place around 
us. For starters, I believe it is timely to review our 
constitution to keep abreast of these changes. 
Having been involved in the review of the 
AOFOG constitution a few years ago and more 
recently the articles of association of FIGO, there 
are areas of our own constitution that need 
modification and updating to withstand new 
challenges.
I sometimes feel that we are in danger of 
becoming the victims of our own success. As 
we have grown in leaps and bounds, the way 
in which we conduct our daily “business” is also 
important. As I have been intimately involved in 
dealings between AOFOG and OGSM over the 
last 2 years, I have had a front row, un-blinkered 
view of how OGSM operates. You only have 
to look to Japan (JSOG) and Taiwan (TAOG) to 
appreciate the efficiency with which they work. 
Even India (FOGSI) is now moving towards ISO 
certification. These are all large organisations 
with members running up to 35,000; should we 
not be doing better with a membership of only 
about 1000? To their credit, recent Councils have 
undertaken SWOT analyses of our Secretariat 
but we need to push on as change has been slow 
in coming.
Finally, it is a truism that the long-term success 
of any organisation lies with the younger 
generation. It is always a tricky business trying 
to achieve a right blend of “older experience” 
with “younger enthusiasm” be it on Council or 
Committees. Going by the information gleaned 
from the various issues of CONNECT, the 
younger generation is being engaged more but 
perhaps we should re-examine the mechanisms 
by which we can give them better opportunities 
to progress within our organisation. Perhaps the 
time has also come to limit the duration that any 
individual can occupy any particular position.
As Heraclitus famously said, “Change is the only 
Constant in Life” and so we must be prepared to 
embrace change quickly lest we are left behind 
and descend to the depths of the “bad and 
ugly” of this region.
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Quo Vadis 
OGSM?
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Looming
Nightmare Of
Menopause:
The Genitourinary 
Syndrome Of 
Menopause
Genitourinary Syndrome of Menopause, abbreviated as GSM, is a new terminology 
approved by the board of directors of the International Society for the Study of 
Women’s Sexual Health (ISSWSH) and the North America Menopause Society in 
2014, to describe the symptoms related to genitourinary tract in consequence 
of menopause1. This new terminology includes the clinical presentation 
associated with oestrogen deficiency involving changes to the female genital 
area; i.e., labia, vulva, vagina, urethra and bladder2. Women may experience 
vaginal dryness, dyspareunia, burning sensation, itchiness, dysuria, etc3. Unlike 
vasomotor symptoms, prevalence of GSM seems to increase with the years past 
menopause, reaching a peak of 80% 10 years after menopause4.
According to The Vaginal Health: Insights, Views and Attitudes (VIVA) survey, 
which involved 3520 post-menopausal women aged between 55 to 65 years, 
about 63% of women failed to recognise vaginal atrophy as a chronic condition 
and almost half of them (46%) lacked knowledge about local oestrogen therapy 5. In 
the same study, 80% of women considered genital atrophy as causing a negative 
impact on their life, with 75% claiming it affects their sexual life, and up to 33% 
suffer on how it affects their relationship and marriage5. In another international 
survey conducted by REal Women’s VIews of Treatment Option for Menopausal 
Vaginal ChangEs (REVIVE), it was found that only 10% of healthcare providers 
actually initiate the conversation about GSM symptoms as expected by women. 
Lack of efficacy and the concern about hormonal side effects were perceived as 
the main limitation for local oestrogen preparation use6. A similar initiative was 
carried out by the Pan-Asian REVICE survey, published in 2017, involving 5992 
post-menopausal women across Indonesia, Malaysia, Singapore, Taiwan and 
Thailand. Among 638 women with GSM, only 35% were aware of this condition, 
whereas only 1 in 5 (21%) had been clinically diagnosed with GSM and less than 
a quarter (24%) was treated for their condition7.
This condition poses a medical challenge and is becoming a public health 
concern, because it is often under-reported by women and under-recognised by 
healthcare providers; hence, women continue to suffer in silence8.
Oestrogen therapy is recognised as the most effective treatment for GSM. Low-
dose vaginal oestrogen therapies are effective and considered safe in treating 
women with GSM9-13. There are a variety of preparations, including creams, 
tablets and rings with minimal systemic effects14,15. In the recent Cochrane 
Review by Lethaby et al. (2016), no difference was found in the efficacy between 
various local oestrogen preparations. There is weak evidence that oestrogen 
cream might be associated with an increase in endometrial thickness, possibly 
due to the higher dose of cream as compared to the oestrogen ring9. Other 
possible side effects of conjugated equine oestrogen (CEE) cream include erratic 
uterine bleeding, breast tenderness and perineal pain16.
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Oestrogen preparation is found to be clinically effective as low as 4 ug for the treatment of GSM10.  Low-dose regimes (7.5 μg 
vaginal ring or 10 μg vaginal tablet) should be preferred to intermediate (25 μg oestradiol or 0.3 mg conjugated equine oestrogen) 
or high dose preparations (50-2000 μg oestradiol or 0.625-2.5 mg conjugated equine oestrogen). A study had substantiated that 
low-dose preparations increased plasma oestradiol levels after long term administration but not above the normal range (≤ 20 
pg/ml)13. The finding was consistent with another study by Rueda et al. which revealed, following treatment with local oestrogen, 
that the serum estriol level rose and peaked in an hour. However, during 6 months of follow up, no rise in the level of serum estriol 
was found among treated women14.
Two recent reviews on topical oestrogen concluded that there was no evidence of endometrial hyperplasia found after 2 years of 
its use. Thus, the literature continue to provide consistent information about the safety of local vaginal oestrogen in low doses 
and does not support the concurrent use of progestin for endometrial protection12,17. In the recent NAMS hormonal therapy 
position statement 2017, it was stated that progestogen is generally not indicated when oestrogen therapy is administered 
vaginally for GSM in low doses, although clinical data to support the safety of endometrium beyond 1 year usage is lacking15.
The use of ultra-low dose vaginal estriol 0.03 mg in combination with Lactobacillus acidophilus KS400 in the treatment of 
postmenopausal vaginal atrophy has been well studied. A randomised placebo-controlled study followed by an open label follow-
up demonstrated the superiority of the 0.03 mg estriol-lactobacilli combination to placebo in which the vaginal maturation index 
(VMI) improved significantly (35.2% vs 9.9%). Furthermore, the VMI increased to 55.4% and remained at a comparable level 
(49.4-52.8%) during maintenance therapy18. Combination of ultra-low-dose vaginal estriol with lactobacilli has been recently 
studied, and the Female Somatic Sexual Experience Instrument (FSSEI) revealed a non-significant trend of improvement. The local 
vaginal therapy with ultra-low-dose vaginal estriol combined with lactobacilli may be a useful treatment in breast cancer survivors 
experiencing atrophic vaginitis19.
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Non-hormonal therapies have provided 
exceptional improvement for GSM. The 
approved treatment of dyspareunia in post-
menopausal women include ospemifeme1 
and intravaginal DHEA2. Ospemifene is a non-
oestrogen, tissue selective oestrogen receptor 
modulator. Ospemifene at the dosage of 60 mg/
day demonstrated a significant greater Female 
Sexual Function Index (FSFI) score as compared to 
placebo at week 4 (p<0.001). The effect persists 
even at week 12 and all domains of FSFI including 
sexual pain, arousal and desire were significantly 
improved (p<0.05)1.  The same dose of ospemifene 
for 20 weeks also showed an improvement in 
physical examination findings on vulvoscopic 
photography in a prospective study by Goldstein 
SW et al2. These changes were also consistent 
with improvement in self-reported pain and 
sexual function2. Overall safety of ospemifene in 
phases 2 and 3 trials suggests some detrimental 
effects on breast and cardiovascular health3. 
However, it revealed a significant improvement 
in the percentage of parabasal and superficial 
cells in the vaginal maturation index (VMI). 
Optimisation of vaginal pH was also noted. 
Non-
Hormonal 
Therapy
For GSM: 
An Update
Dr Ng Beng Kwang / 
Dr Janisha Silva Raju
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The majority of treatment-emergent adverse events were 
considered mild to moderate in severity4. Hence, ospemifene 
was approved by the Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) for the treatment of 
moderate to severe dyspareunia. 
Dehydroepiandrosterone (DHEA), a sex steroid, has been shown 
to improve VMI and vaginal pH in one week5. In a prospective 
study, the daily use of intravaginal 0.5% DHEA (Prasterone) for 
12 weeks had improved sexual arousal/sensation domain by 
68%, arousal/lubrication by 39%, orgasm by 75% and dryness 
by 57%6. Recent study by Labrie et al. (2018) revealed that 
percentage of parabasal cells decreased by 27.7% over placebo, 
and percentage of superficial cells increased by 84.4%. Whereas 
the vaginal pH decreased by 0.66-unit pH, and pain at sexual 
activity reduced by 1.42 severity unit. Upon gynaecological 
evaluation, vaginal secretions, epithelial integrity and epithelial 
surface thickness and colour improved by 86%7. However, the 
ISSWAH expert consensus panel review of 2018 concluded 
that vaginal DHEA is effective in managing dyspareunia in 
menopause, yet further studies are needed8.
Of late, laser therapy has been gaining popularity. It enhances 
the production of collagen and extracellular matrix, hence 
optimising the vaginal tissue thickness by making it more firm 
and elastic9. Salvatore S et al. reviewed 10 vaginal specimens 
following laser therapy and found that vaginal connective 
tissue was remodelled without causing damage to surrounding 
tissue10. A pilot study by Salvatore et al. discovered that 12 
weeks fractional laser therapy was a feasible approach and 
is effective for improving vulvovaginal symptoms (vaginal 
dryness, burning, itching, dyspareunia and dysuria) as well as 
vaginal health index score (VHIS)11.
Pitsouni E et al. published a systematic review on the use of laser 
therapy in GSM. This included 14 studies involving 542 patients 
suffering from GSM. The author concluded that laser therapy 
appears promising as it may reduce the severity of symptoms, 
improve quality of life and restore the premenopausal vaginal 
mucosal status. However, the quality of evidence is poor and 
thus, it was still not recommended by the evidence-based 
modification of the current practice12 until robust evidence is 
available.
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Female sexual dysfunction (FSD) is a prevalent problem afflicting 
approximately 40% of women1-5. It is a sexual problem associated with 
personal distress. It takes different forms, including lack of sexual desire, 
impaired arousal, inability to achieve orgasm or pain with sexual activity6. 
For many women, the phases may vary in sequence, overlap, repeat or be 
absent during some or all sexual encounters. It is a complex and poorly 
understood condition that affects women of all ages. It is more typical 
as women age and is a progressive and widespread condition. Sexual 
dysfunction may be a problem since the start of sexual activity or may be 
acquired later in life after a period of normal sexual function.
Female Sexual Response Model
An understanding of sexual response is helpful in the evaluation and 
treatment of sexual dysfunction.
In 1966, Masters & Johnson found that sexual response is divided into four 
phases: excitement, plateau, orgasm and resolution. These four phases 
occur in a linear way, with one coming after the other. The sexual response 
cycle isn’t complete without all four occurring (Figure 1).
Female Sexual 
Dysfunction
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In 1974, Helen Singer Kaplan introduced another 
linear model. She added the concept of desire 
to the model and condensed the response into 3 
phases: desire, excitement and orgasm. This model 
gives the same importance to the physiological 
and psychological aspects of sexual response. 
Masters & Johnson and Kaplan’s models were 
intended to reflect sexual response for males and 
females; however, researchers have recognised 
that some women do not experience all four 
phases of the cycle. As such, these models have 
been criticised since they do not reflect a woman’s 
actual experiences.
In 2001, Rosemary Basson published a non-linear 
model of female sexual response that incorporated 
the importance of emotional intimacy, sexual 
stimuli and relationship satisfaction7. Basson’s non-
linear model of sexual response incorporates the 
need for intimacy, acknowledges that desire can 
be reactive or spontaneous and may come either 
before or after arousal, recognises that orgasms 
may contribute to satisfaction but aren’t necessary 
for satisfaction and considers relationship factors 
that may impact the cycle as costs or rewards7 
(Figure 2).
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The endocrinology of female sexuality is uncertain. 
Oestrogens and androgens are involved but the 
magnitude of their roles require further clarification. 
Role of oestrogens — Declining levels of oestrogens in 
peri- and postmenopausal women have been associated 
with changes in sexual function. The major reasons 
are the effects of hypoestrogenism on vulvovaginal 
tissues and the pelvic floor. Vasomotor symptoms may 
also cause discomfort or sleep disturbance that impact 
sexual function.
Role of androgens — Androgens likely play a role 
in female sexual function; however, the magnitude 
of this role is uncertain8. Most physiologic models do 
not suggest that androgen levels correlate with female 
sexual function. However, supraphysiologic doses of 
androgen therapy have been found to increase libido 
or sexual frequency.
Sexual function is strongly affected by relationship and 
sociocultural factors, in addition to physiologic and 
psychological issues. A history of physical or sexual abuse 
is strongly associated with female sexual dysfunction. 
Menopause is consistently associated with dyspareunia. 
The effects of age and menopause on female sexual 
dysfunction considerably vary among women. In 
general, sexual problems increase with age, but 
distressing sexual problems peak in midlife women. 
Hormonal contraception, including oestrogen-progestin 
contraceptives, is unlikely to interfere with female 
sexual function.
Depression and anxiety are strongly associated with 
female sexual dysfunction. Other associated medical 
conditions include urinary or faecal incontinence, 
chronic pain conditions, substance abuse, end-stage 
renal disease and cancer. 
Medications, specifically certain antidepressants 
(selective serotonin reuptake inhibitors), are associated 
with female sexual dysfunction. Other agents, including 
beta-blockers and antipsychotics, may contribute to 
sexual problems. 
Definition and Classification
Traditionally, female sexual dysfunction has been 
classified into four categories by the Diagnostic and 
Statistical Manual of Mental Disorders, 4th ed. (DSM-
IV): sexual desire, sexual arousal, orgasmic or sexual 
pain disorders9. However, the definition of normal 
female sexual function was critically examined, and the 
accepted definition and classification of female sexual 
dysfunction was subsequently revised6.
Clinical Approach
Sexual function issues should be addressed as part 
of every comprehensive women’s health visit. 
Unfortunately, most sexual problems in women remain 
unrecognised and untreated. Asking a patient whether 
she has sexual concerns can be easily incorporated into 
clinicians’ questions about gynaecologic health, along 
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with asking whether she is sexually active, practices safe sex, 
uses contraception (if indicated) and has any current or past 
issues with sexual abuse.
Many clinicians avoid asking about sexual concerns because 
they don’t feel they have the time or knowledge to address 
these issues. A useful strategy for clinicians is if a sexual concern 
is raised and does not require immediate attention (e.g., patient 
is unsafe or at high risk of a sexually transmitted infection), 
the clinician may defer full evaluation and treatment until a 
follow-up visit or refer the patient to a clinician experienced 
in sexual health. The patient is often relieved at being asked 
and can be comforted by being told that you appreciate her 
sharing her concerns, many women experience sexual problems 
and effective treatments are available. While waiting for the 
follow-up visit, encourage your patient to read about sexual 
problems in women.
At the follow-up visit, a detailed history of the sexual problem 
is essential. By identifying the onset of the problem and 
contributing factors, the appropriate intervention is often clear. 
If a women experiences low desire upon reaching menopause 
and this is with associated vaginal dryness, dyspareunia, hot 
flushes and sleep disruption, treatment of her menopausal 
symptoms is likely to improve her low libido. If problems 
with arousal and orgasmic response began after the onset 
of depression or initiation of a selective serotonin reuptake 
inhibitor, sexual function should improve with treatment of 
the mood disorder and/or use of an antidepressant that is less 
likely to affect sexual function, such as bupropion. Addressing 
sources of pain or discomfort during sexual activity (e.g., pain 
from arthritis, urinary or faecal incontinence) often improve 
sexual interest and satisfaction.
Sexual health concerns are usually multifactorial. Relationship 
and family issues often play a role as do work or other sources 
of stress. Women may experience poor body image or a feeling 
of embarrassment or shame. Women should be informed that 
they are not alone as sexual problems are common and just 
sharing a concern and wanting improvement is a good first 
step.
Diagnostic Evaluation
The evaluation of female sexual dysfunction includes a medical 
and sexual history. A pelvic examination is only required for 
diagnosing sexual pain disorders, but an examination is 
important for all patients with sexual complaints to identify 
possible etiologic factors and associated conditions10. 
Laboratory testing and imaging are required only to evaluate 
associated conditions, as appropriate.
Diagnostic criteria — The American Psychiatric Association 
(APA) guidelines for sexual disorders require that a sexual 
problem be recurrent or persistent and cause personal distress 
or interpersonal difficulty to establish diagnosis9. Additionally, 
the problem must be present for at least six months and not be 
accounted for by a different diagnosis (e.g., depression).
Sexual dysfunctions are defined in relation to one or more phases 
of the sexual response cycle. Although in clinical practice, it is 
uncommon to see a disorder that is limited to a single phase9. 
In the diagnostic criteria published in 2013, several categories 
were combined, and definitions were changed6. 
Treatment
Treatment varies by disorder and cause; often, more than one 
treatment is required because disorders overlap. Sympathetic 
understanding of the patient and careful evaluation may 
themselves be therapeutic. Contributing factors are corrected 
if possible and mood disorders are treated. Explaining what is 
involved in the female sexual response may also help.
CONNECT  •  Issue 6
9
Most women with Endometrial Cancer (EC) are diagnosed at an early stage. 
Early stage EC carries good prognosis and low relapse rate. Hence, patients 
are more likely to suffer from the morbidity of treatment rather than from EC 
itself.
In our country, around 1100 of new endometrial cancer cases were diagnosed 
in 20181.
No standard practice is present on the extent of surgery for low risk/early 
stage endometrial cancer. Low risk patients include those with stage 1, small 
tumour (<2 cm), endometroid subtype, Grades 1 or 2. Quite often, treatment 
include hysterectomy, removal of adnexal structures and performing a full 
pelvic lymphadenectomy (PLND). However, most women with early stage/low 
risk disease have negative lymph nodes2, and full pelvic lymphadenectomy is 
associated with significant lymphatic morbidity. Risk of lower limb lymphedema 
after full PLND is 5%-35% based on various studies3. 
Performing PLND at an early stage of EC is still questionable as two randomised 
trials4,5 have shown no survival benefit, particularly in low-risk endometrial 
cancer patients.
By not doing PLND during the early stage of EC, lymphedema risk can be 
avoided but at the expense of a small percentage of women. Hence, Sentinel 
Lymph Node Biopsy (SLNB) offers an answer to this dilemma.
The feasibility of Near Infrared Indocyanine Green (NIR-ICG) SLNB as an 
alternative to systematic pelvic lymphadenectomy for surgical staging in 
low risk endometrial cancer has been confirmed by a few studies6,7. In our 
region, a pilot study at KKH (Singapore) with SLN mapping using ICG-NIR was 
conducted in 35 patients with early-stage endometrial cancer who underwent 
laparoscopic staging surgery. SLN was first biopsied, followed by systematic 
pelvic lymphadenectomy. The mean lymph node count was 21 nodes and the 
mean number of sentinel lymph node (SLN) biopsied was three nodes per 
patient. The overall SLN detection rate was 97% (34 in 35 patients) and the 
rate of bilateral mapping – the successful identification of SLNs on both sides 
of the pelvis – was 88.6% (31 in 35 patients). It was found that two patients 
(5.7%) had positive bilateral pelvic lymph nodes, two patients (5.7%) had 
positive SLNs and no patient had false-negative SLNs. 
During my fellowship at KKH, I was tasked to look into the comparison of 
lower limb lymphedema rate post NIR-ICG sentinel lymph node biopsy versus 
full pelvic lymphadenectomy in early stage endometrial cancer. 135 women 
(29 SLNB/106 PLND) were analysed; the incidence of lower limb lymphedema 
3 months post-surgery in the SLNB group was 3.4% compared to 21.7% in the 
full pelvic lymphadenectomy group (p=0.023). We are anticipating more data 
from the SLNB group and from the 9-month assessment.
In conclusion, SLNB in the early stage of Endometrial Cancer is the way forward 
to avoid lymphatic complications of full PLND.
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The role of vitamin D in women’s health and perinatology is a subject of 
major interest in the past few years. Malaysia, despite geographically 
being a sun-enriched area, has a high prevalence of vitamin D deficiency. 
A recent study has shown that prevalence of Vitamin D deficiency was 
up by 71.7% among pregnant women when tested during their third 
trimester.
Vitamin D (calciferol) is a pro-hormone that is derived from cholesterol. 
The nutritional forms of vitamin D include D3 (cholecalciferol) which 
is generated in the skin under direct exposure to sunlight, especially 
ultraviolet B (UVB) photon, and Vitamin D2 (ergocalciferol) which is 
Role Of
Vitamin D
In Women’s
Health
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derived from food. Vitamin D has a well-known classical function in calcium uptake and bone metabolism. But more recent works 
have highlighted the importance of the non-classical actions of vitamins D in innate and adaptive immune systems, pancreatic 
ß-cells, cardiovascular system and the brain. Tissue responses included effects on hormone secretion, modulations of immune 
response and regulations of cell proliferation and differentiation. 
Vitamin D and pregnancy outcomes
Vitamin D deficiency has been reported to increase the risk of gestational diabetes mellitus, pre-eclampsia, anaemia, bacterial 
vaginosis, threatened preterm labour, caesarean section and low birth weight baby. Nevertheless, some studies presented 
conflicting results due to multiple confounding factors. Thus, the full implication of vitamin D deficiency during pregnancy is yet 
to be discovered. Studies have evaluated mothers in the third trimester and correlated their serum vitamin D levels with new-
born’s cord blood as well. The mother’s vitamin D storage is the infant’s basic source of vitamin D as breast milk is poor in this 
nutrient. 
Polycystic ovarian Syndrome 
There is increasing evidence that supports the contribution of vitamin D deficiency to metabolic disturbances in women with 
PCOS, including insulin resistance, obesity, hypertension and menstrual dysfunction. Evidence suggested that polymorphism in 
the vitamin D receptor gene was associated with vitamin D deficiency in PCOS and its metabolic and endocrine disturbances. 
However, the exact mechanism is still not fully understood. Vitamin D may play a role in glucose metabolism by enhancing insulin 
synthesis and release. It was also shown to increase insulin receptor expression and suppression of pro-inflammatory cytokines 
that possibly contribute to the development of IR. IR reproductively causes hyperandrogenism through elevation of ovarian 
androgen production and the reduction of sex hormone-binding globulin (SHBG) production. 
Infertility 
Several studies investigated the role of vitamin D in ovarian physiology and its implication for reproduction. So far, studies 
showed conflicting results that either confirms that vitamin D may be a positive regulator of AMH production, or that its level is 
unrelated in the ovarian reserve or ovarian response after ovarian stimulation.
Uterine Fibroid 
Researchers found that African-American women, who are at increased risk of fibroid due to higher melanin concentration, result 
in decreased serum vitamin D levels and reduced expression of vitamin D receptors in the adjacent myometrium compared to 
white women.
Thus, vitamin D supplementation in women is considerable, but more high-quality data are still necessary. Recent evidence seems 
insufficient to guide new clinical recommendations. 
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Mainstreaming Cancer Genetics may be feasible in Malaysia. It 
can pave the way to improving access to ovarian cancer genetic 
testing and help identify mutation carriers who may benefit 
from risk management and targeted treatment, as recently 
suggested by the preliminary results of the MaGiC Study 
presented at the 3rd MaGiC Investigators’ Meeting in Subang 
Jaya. 
“This is the first nationwide study for ovarian cancer and to 
assess whether we can improve access to genetic counselling 
and genetic testing for ovarian cancer by mainstreaming”, 
said lead author Ms Sook-Yee Yoon, genetic counsellor, Cancer 
Research Malaysia, Subang Jaya, Malaysia. “Genetic testing is 
underutilised in our country to identify high risk individuals 
and their family members who may benefit for understanding 
their risk to cancer. The information may also have therapeutic 
impact”.
Mainstreaming genetic counselling for genetic testing of BRCA1 
and BRCA2 in ovarian cancer patients in Malaysia (MaGiC Study) 
was set up to: 1) assess the prevalence of germline BRCA1 and 
BRCA2 mutations among ovarian cancer patients; 2) determine 
the feasibility of mainstreaming genetic testing and counselling 
at local hospitals; and 3) examine the psychosocial impact of 
genetic testing in Malaysia.
The study was designed to recruit 800 ovarian cancer patients. 
Basic genetic counselling workshops were held for 68 non-
genetic clinicians including gynaecologists, oncologists and 
clinical geneticists from 23 hospitals across Malaysia. Patients 
were either directed to counselling by a trained non-genetic 
clinician in their local hospitals in a clinical programme led 
by Professor Yin Ling Woo (MaGiC’s lead clinician), or to 
counselling by a genetic counsellor or clinical geneticist in a 
programme led by Professor Meow Keong Thong (lead clinical 
geneticist at specialised centres in Kuala Lumpur).
All blood samples were analysed for BRCA mutations by the 
Cancer Research Malaysia led by Dr Joanna Lim who is the 
diagnostic lead. Patients receive pre-test counselling, followed 
by test results and post-test counselling. After both pre- and 
post-test counselling, they were interviewed by a researcher 
over the phone to assess feasibility and psychosocial impact 
of the experience. Interviews were based on scales adapted 
for use in Malaysia. These included the Genetic Counselling 
Satisfaction Scale, the Decisional Conflict Scale, the Psychosocial 
Aspects of Hereditary Cancer (PAHC) questionnaire, the Distress 
Thermometer and the Cancer Worry Scale. Interview results 
were compared between the two study arms.
Two years into the study, 700 patients have been counselled 
and provided with genetic testing. 90 (13%) patients were 
identified to have BRCA mutations. “Around 13% of those 
tested were BRCA mutation carriers which is similar to that 
found in other populations,” said Yoon. “We found carriers 
throughout the country and are working with local clinicians 
to establish protocols in local hospitals that have not managed 
patients with known BRCA mutations before”.
In terms of feasibility, patients in local and specialised 
counselling arms were equally satisfied or very satisfied with 
the counselling they received. The local counselling arm has 
Mainstreaming Cancer Genetics 
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been recruiting patients more quickly than the specialised arm. 
“Patients seem to prefer local appointments, so if they are 
referred to another centre for genetic counselling, they seem 
less likely to attend” said Yoon.
Preliminary results show that the answers to the psychosocial 
surveys were similar between the two groups. Most patients 
were satisfied with their counselling experience, felt informed 
about their choices and found it easy to decide to continue with 
genetic testing. Yoon mentioned, “These are preliminary results 
but mainstreaming of genetic counselling in Malaysia may be 
a feasible model  to improve access to genetic testing services 
or patients with ovarian cancer. If successful, this model could 
be adopted for other cancers and in other parts of Southeast 
Asia”.
“Cancer is still a taboo subject in Malaysia and there is a 
fatalistic attitude to hereditary conditions” continued Yoon. 
“Genetic information can cause conflict in families and the data 
we are collecting on the psychosocial impact of genetic testing 
will provide insight into the psychosocial challenges. With this 
knowledge, we can focus on interventions to overcome these 
challenges”.
Commenting on the study, Prof Woo said, “In the past, genetic 
testing in ovarian cancer was limited to a small number of 
patients with the aim of identifying relatives at risk. Now that 
there is a drug to treat cancer patients with BRCA mutations, 
genetic counselling and testing is recommended for all patients 
with epithelial ovarian cancer. This has increased the number 
of patients who qualify for testing and specialised centres may 
become overloaded”.
“Mainstreaming genetic testing and counselling to local 
hospitals is a strategy to cope with this increased volume of 
patients” continued Prof Woo. “This is ideal for a large country 
like Malaysia where specialised centres are concentrated in 
the capital, yet the majority of the population live elsewhere. 
Patients found to have a BRCA mutation still need to be referred 
to a specialised cancer genetic clinic, but it becomes a smaller 
group”.
“This study shows that moving the genetic counselling process 
to the community may be feasible and could be rolled out 
across Malaysia. It also is a model for other countries in the 
region to follow” said Prof Woo. 
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Premature ovarian insufficiency (POI) affects 1 in 10,000 women 
by the age of 20 and one in 100 by the age of 40 years1. POI 
can be referred to as either primary ovarian insufficiency or 
premature ovarian insufficiency. It is characterised by a triad 
of 4-6 months of amenorrhea,  high levels of gonadotropins 
and low levels of oestradiol in women before the age of 402. 
Formerly known as premature ovarian failure or premature 
menopause, the condition could be transient or progressive. 
POI is postulated to be due to three mechanisms; i.e., congenital 
decrease in primordial follicles, accelerated follicular atresia and 
the inability to recruit primordial follicles3. However, for most 
of the 74-90% of cases, the cause is essentially unexplained4,5.
Multifactorial in aetiology (among the identifiable causes 
of POI) are genetic, autoimmune, metabolic dysfunction, 
infectious and iatrogenic6. Classical presentation is with oligo- 
or amenorrhoea. Some may show symptoms of oestrogen 
deficiency. Diagnosis of POI is life-changing and crippling 
as it negatively impacts physical and psychosocial aspects. 
Osteoporosis, accelerated cardiovascular aging, neurocognitive 
disorders and infertility are among the long-term effects due 
to oestrogen deficiency in POI. In 5-10%, varying degrees of 
residual ovarian function may still exist, thus they may be able 
to conceive spontaneously7. To date, there are still no available 
biomarkers to accurately predict POI. Although proper 
diagnostic accuracy is lacking, the POI Guideline Development 
Group (GDG) recommends the following diagnostic criteria:8 
i) oligo/amenorrhoea for at least 4 months, and
ii)  an elevated FSH level > 25 IU/l on two occasions > 4 weeks 
apart.
Investigation-wise, chromosomal analysis and karyotyping are 
crucial to be sent for to all non-iatrogenic POIs such as Turner’s 
syndrome. Fragile-X pre-mutation testing is warranted. 
Screening for 21OH-Ab (or alternatively, adrenocortical 
antibodies (ACA) and thyroid (TPO-Ab antibodies) should be 
performed in women with POI of unknown cause or if an 
immune disorder is suspected8. Due to prolonged oestrogen 
deficiency, bone mineral density (BMD), (BMD) testing is 
indicated as well as diagnosis; especially if ovarian insufficiency 
is suspected to have occurred for a long period and once 
treatment commences, repeated within 5 years10.
The sequelae for POI include psychological distress and low self-
esteem as a consequence of the life-altering diagnosis9. Hence, 
explaining the diagnosis should be done face-to-face and 
not via telephone. Referral to a psychologist and continuous 
emotional and social support are essential9.
Women with POI due to Turner’s syndrome require a full work-
up and referral to cardiologist, endocrinologist, geneticist 
(especially if there is Y chromosome) as well as to the ENT, 
ophthalmology specialists and psychologists. The presence of 
a Y chromosome requires a gonadectomy to be performed. 
Thyroid function tests should be done annually and the patients 
monitored for hypertension. They should also be counselled 
on the increased  risks of impaired glucose tolerance and liver 
problems. 
Hormone replacement therapy (HRT) is indicated in women 
with POI to induce breast development and menstruation 
in those with delayed puberty and also for maintenance of 
cardiovascular and bone health9,10. HRT should continue until 
the age of natural menopause; i.e., around 50 years of age. 
The reader is advised to read other articles on POI regarding 
the recommended HRT regimes for women with POI as this 
is beyond the scope of this article. Calcium and vitamin D 
supplementation as well as maintaining a healthy lifestyle are 
advocated for bone health. Local oestrogens may be required 
for dyspareunia and genito-urinary symptoms10.
Due to the possibility of spontaneous conception, women with 
POI who wish to avoid pregnancy may require contraception 
in terms of barrier method or possibly an intrauterine device9. 
Nevertheless, this is a rare occurrence and women with POI 
need to be counselled that as yet, there are no interventions 
to increase ovarian activity and conception rates10. Fertility 
options include adoption, foster parenthood, oocyte donation 
and embryo donation; depending on religious and local laws. 
Women with Turner’s syndrome have very high obstetric risks 
thus, if they wish to conceive, they should be referred to 
a cardiologist for evaluation as well as have a general and 
medical assessment prior to conceiving10.
There is presently a lack of sufficient high-quality evidence for 
long-term interventions on women with POI; this should also be 
explained to these women9,10. Much research is being carried out 
at present. It is hoped that these studies will provide guidance 
in future. Such women require multidisciplinary care and a 
lot of emotional support as this diagnosis is devastating. The 
PAG unit in HCTM UKMMC has noticed a worryingly increasing 
trend of patients referred to us for primary and secondary 
amenorrhoea due to POI. We are active in conducting research 
on POI and look forward to presenting our results soon. 
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The vaginal approach is the natural route of excellence, 
also known as “natural orifice hysterectomy” or “no 
scar hysterectomy”. It seems to be the current trend 
in minimally invasive context for urogynecological 
procedure, which follows all criteria of minimally 
invasive surgery. Vaginal hysterectomy (VH) is a long-
practiced procedure since the fourteenth century 
(Berengario de Carpi, 1470–1550). Non-descent vaginal 
hysterectomy (NDVH) was introduced later in 1934, 
pioneered by Haeney. In the United States, the trend is 
now more towards NDVH, especially with the presence 
of new tools (vessels sealing device), new techniques 
and changes in contraindications of the procedure.
The American College of Obstetricians and 
Gynaecologists (ACOG 2017) strongly recommends 
that VH is the approach of choice whenever feasible 
for all benign gynaecological conditions. The Cochrane 
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Table 1: Indications for NADVH
Indications Percentage (%)
Uterine fibroid 56.7
Endometrial hyperplasia 21.3
Adenomyosis 7.3
Chronic cervicitis 6.0
DUB 6.0
CIN 2.6 
Dhivya B & Gharphalia D et al.; J Clin Diagn Res, 2016
Table 2: Advantages of NDVH compared to other approaches
                            Abdominal                                 Laparoscopic
• Less surgical time • No significant difference in post-operative recovery
• Fewer post-operative complications • More rapid learning curve 
• Less painful post-operative recovery • No complication related to pneumoperitoneum/ trocar
• Fewer hospitalisation days • General anaesthesia is not mandatory
• Less social cost • Fewer cost: less sophisticated equipment’s & logistic
• Lack of scar complications
• Less risk in cases of other associated diseases
Pelosi MA, 1998; Kovac SR, 2014; SS Sheth, 1991
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Systematic Review (2005) based on 47 studies concluded 
that VH has the best outcomes compared to abdominal and 
laparoscopic route. International Society for Gynecologic 
Endoscopy (ISGE) also concluded that NDVH is the best 
choice for many gynaecological patients where hysterectomy 
is indicated. However, it is difficult to explain why VH is not 
preferred globally among surgeons, including in Malaysia.
Advantages of the vaginal route include less surgical time. 
Closing the abdominal wall is also not required; therefore, 
there is less risk of post-operative wound complications. The 
incidences of post-operative paralytic ileus, flatulence and 
adherences are diminished due to minimal peritoneal incision 
and handling of intestines. Post-operative recovery is less painful 
and much faster. Compared to laparoscopy, it does not require 
general anaesthesia, has a faster learning curve and has less 
risk of ureteric injury. VH requires less sophisticated instruments 
and logistics, therefore it involves very minimal cost. 
The literature clearly reveals that VH can be accomplished in 94-
97% of cases with the absence of uterine prolapse (Pierluigi et 
al., 2004). Surprisingly, for years, most surgeons have classified 
vaginal hysterectomy as a procedure limited to uterine 
prolapse. This reflects the ignorance of many concerning the 
updated literature. Treatments are considered unprofitable for 
the industry, hence had gained inadequate support. 
The conditions that led surgeons to believe that the vaginal 
route is not a suitable option includes no prolapse, big uterus, 
history of caesarean or pelvic surgery, nullipara, no vaginal 
delivery or the patient needs an oophorectomy. The fact that 
these are just simple myths must be pointed out. It is actually 
the surgeon’s experience and skills that play the decisive role.
Common challenges that surgeon may encounter include: 
inadequate exposure and visualisation (especially in virgin 
vagina or nulliparity), entering the cul-de-sac, securing vascular 
pedicles in limited space, adhesion due to previous surgery, 
removal of big uterus, the need of oophorectomy and the 
Table 3: Patient’s selection criteria
Guidelines on the Selection of the route of hysterectomy
as recommended by ACOG 2017
1. Size and shape of the vagina and uterus
2. Accessibility to the uterus (e.g., uterine descent, pelvic adhesions)
3. Extent of extra uterine disease
4. The need for concurrent procedures
5. Surgeon training and experience
6. Available hospital technology, devices, and support
7. Case is emergent or scheduled
8. Preference of the informed patient
Table 4: Contraindications for NDVH
Traditional Evidence based contraindication
• Previous pelvic surgeries • Malignancy
• Present of adnexal mass • Undiagnosed pelvic mass
• Nulliparity/no prior vaginal delivery • Inability to access uterine vessel
•  >12 weeks size uterus
• Pelvic pain
• Endometriosis
• Inaccessibility - arch < 900 vaginal stenosis
• Malignancy 
presence of extrauterine pathology. The proper positioning of 
the patient, good lighting, good retractor and use of vessels 
sealing systems make NDVH easier. When facing a large uterus, 
Morcellation techniques, which were widely known since 1880–
1890, provide the possibility to overcome surgical limitations. 
The techniques include bisection, coring, myomectomy, wedge 
resection, spiral incision, cervical amputation and cervical 
wedge. Usually, these techniques are used in combination. 
Prior to the removal of a large uterus, preoperative sonography 
is very useful and important to further confirm the diagnosis 
(fibroid or adenomyosis) and obtain details on fibroids, adnexal 
pathology and calculation of uterine volume. Antero-posterior 
and transverse diameter of the uterus is very important 
to determine the uterine-free pelvic space for operative 
manoeuvrability. Uterus size of 18 weeks by clinical palpation 
can be easier to remove compared to a 10-week size uterus but 
with wider transverse diameter/high volume.
Concomitant oophorectomy is successfully done in 94% of 
cases. The operating time increases by less than 30 minutes 
with no added complications (S.S Sheth, 1991; Pierluigi et al., 
2004). Special equipment may be needed such as ovarian clamp, 
headlight and long roller gauze pack. Oophorectomy is easily 
performed using “the round ligament technique” introduced 
by Magrina JF (1999).
Preliminary laparoscopy has a role in the pelvic assessment 
for suspicious extra-uterine disease such as adnexal 
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pathology, severe endometriosis and adhesion. Transvaginal endoscopic 
oophorectomy (TVEO) is useful to remove highly located ovary. 
The approach is aborted if there is no further descent despite morcellation 
and inability to control profuse bleeding during morcellation. Complications 
are rare even with “difficult” cases, which includes haemorrhage prior to 
morcellation. Others such as vault haematoma, urinary tract infection and 
backache did not significantly increase (Gitsch G et al., 2004). The risk of 
ureteric injury is rare compared to laparoscopic surgery.
CONCLUSION
NDVH is the least expensive and invasive procedure with the lowest 
morbidity risk and the most rapid post-operative recovery. It is safe and 
feasible in the hands of trained, creative and determined vaginal surgeons. 
A thorough pre-operative assessment and examination prior to surgery is 
important. Debulking procedure is safe and it can be accomplished via 
vaginal route in most cases. Patients should be informed about the best 
options available and be involved in the decision making.
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Indeed, there is much confusion, concern and great debate 
about this. While many have chosen to ignore this subject in its 
entirety, the inconvenient truth is that Aesthetic Gynaecology 
is actually a sub-component of our speciality that may actually 
provide health benefits to women. The fact of the matter is that 
our ignorance may be largely due to our lack of understanding 
of the intricacies of aesthetic gynaecology. This article is not 
meant to sing the glories of aesthetic gynaecology but to 
instead plead the case that we as a fraternity should be open 
to assessing its virtues in balanced manner. 
A primary concern, especially with the purists amongst us, 
is that we believe that doctors are trained to treat and heal 
diseases. To them however, aesthetics is nothing more than 
simply beautifying something that is already perfect. Therefore, 
as there is no ‘disease’ to be treated, there is no ‘doctoring’ to 
be done! 
The truth is that aesthetic gynaecology has a role to play in 
many situations. 
Women who have been forcibly subjected to   female genital 
mutilation grow up realizing that they have been butchered. 
Treatment is therefore not merely about removing the scar 
tissue. It is also to rectify the damage that has occurred over 
many years and bringing back the form to as close as possible 
as nature had intended.
Others may have suffered severe trauma following vaginal birth 
that has not been repaired adequately or where healing was 
complicated by infections. These women actually come to us 
dissatisfied years later, complaining of pain and disfigurement. 
Certainly, there can also be a psychological component to their 
symptoms but many can be helped. 
And there are yet other women who present with a myriad 
of complaints. Who are we to judge if these complaints are 
based on ‘true’ pathology or ‘perceived’ pathology? Certainly, 
many of these women can also be helped. After all, aesthetic 
gynaecology is not only about using lasers but actually includes 
surgery to repair disfigured perineums, the correct and timely 
utilization of threads, fillers, fat transfers and possibly also 
PRP (but this is debatable in Malaysia). Even simple hair 
removal at the genital area and bleaching offers patients 
great psychological help. Vaginismus, which can provide 
a formidable strain on a marriage can now be treated with 
botulinum injection into the pubo- coccygeous muscle which is 
also the domain of aesthetic gynaecology.
Therefore, aesthetic gynaecology is not only to beautify, but 
it is also to improve the form and function of the female 
genital. Last but not least, aesthetic gynaecology is very 
prominent in its role in sexual dysfunction especially to 
increase sexual gratification. There have been much said about 
vaginal tightening. There are also procedures that can be 
done to amplify the G-spot in order to achieve higher sexual 
gratification.
However, whenever a procedure is being done, regulation is 
important because we need to be aware of the capabilities 
of the different machines that are available especially when 
usage of lasers are involved as the different modalities used 
can have varying effects, consequences and complications.
Training in aesthetic gynaecology has now become a 
contentious issue that needs to be addressed with urgency. 
There are at present no clear guidelines on training 
requirements nor regulations for doctors performing these 
procedures. This inevitably leaves a lot of room for mishaps, 
which needless to say, will give fraternity a bad name. We must 
therefore, recognize that although aesthetic gynaecology is a 
relatively new area, it is rapidly expanding due to an incredibly 
high demand. We as a fraternity must initiate clear guidelines 
that ultimately protects both the patient and the doctor. 
At present, due to lack of direction from the Gynaecology 
fraternity, it would appear that the bulk of the gynaecological 
aesthetic work is by default being carried out by the general 
practitioners or even by many individuals without medical 
qualifications. It is therefore not surprising that errors and 
complications are becoming common. It would therefore seem 
only logical that the fraternity formalize a working group that 
can initiate a thorough review of the situation, discuss with the 
Ministry of Health on what an ideal training program should 
look like, prepare guidelines and to perhaps actually run 
training programs for interested members of the fraternity.
Lastly, it is entirely expected that any new field in medicine 
is greeted with much skepticism. The same problem greeted 
the fertility fraternity at the beginning. However, now the 
situation is dramatically different. They would not have 
achieved their current level of maturity without regulation. 
The field of aesthetic gynaecology has got the same potentials. 
It will help women to empower themselves and feel great 
about themselves, through many ways. It is time to take the 
bull by the horn and take the lead in this new exciting field! 
Aesthetic
Gynaecology –
The Unspoken
Revolution
Does aesthetic gynaecology merely refer to designer vaginas?
Or does it go beyond that? Does it harm rather than heal?
Dato Dr Mohamad Rafi Mohammed Feizal
Founder of Hospital UMRA
Special interest in fertility, Sexual Health & Asthetic Medicine
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Dr. Premitha Damodaran
Consultant Obstetrician and Gynaecologist
The idea to start a CLINICAL PRACTICE GUIDELINE 
for Menopause Management in Malaysia was 
conceived soon after the last MISCOG. As the 
last CPG on Hormone Therapy was done in 2012, 
there was certainly a large void to be filled with 
new emerging trends, new research and a better 
directed approach to managing the menopausal 
woman.
This CPG is a joint venture between the OGSM 
and the Malaysian Menopause Society and 
funded by a total of 11 pharmaceuticals who are 
involved in the management of a menopausal 
woman. The first meeting was held on 12.08.18 
and a total of 7 meetings have been held to date 
all in the OGSM offices.
On the 24th of February we had a representive 
from the MOH, Dr. Mohd Aminuddin who helped 
give us a clear outline of the various aspects we 
need to look for, how the CPG has to be written, 
the disclosures, the referencing and various 
other aspects. This gave us a clearer guideline to 
what needed to be done.
The compilation of data of the CPG is complete. 
What is needed and is an ongoing process 
presently is:
1. Correction of the text material
2. Filling of the missing links
3. Referencing
4. Search material data as requested by MOH
5.  Review by internal (7) and external 
reviewers (2)
6. Submission to the CPG board.
Unfortunately this last process is tedious and 
may take the longer time frame. We are hoping 
to bring it out in the next 6 months.
The core working committee is as follows: Dr. 
Premitha Damodaran (Consultant ObGyn and 
Chairperson), Dr. Ho Choon Moy (Consultant 
ObGyn, President MMS), Dr. Ng Beng Kwang 
(Consultant ObGyn, UKM Medical Centre), Dr. 
Raman Subramaniam (Consultant ObGyn, FMG), 
Prof Emeritus Dato Dr. Nik Mohd Nasri (Professor 
of ObGyn, University Sains Islam Malaysia), Prof 
SP Chan (Consultant Endocrinologist, SJMC), 
Professor Jamiyah Hassan (Professor of ObGyn, 
University Malaya Medical Centre), and Professor 
Dr. Nik Haslina Nik Hussain (Professor of ObGyn, 
Univerisity Sains Malaysia).
ICOE Report
(Jan – June 2019)
Dr Gunasegaran PT Rajan
ICOE Steering Committee
1. ICOE
A total of 11 ICOE activities were successfully conducted locally and overseas 
training 57 midwives and 165 doctors. The summary is in the table below and 
it continues on a punishing schedule averaging almost 2 courses monthly. 
Nepal  15 – 17 Feb 24 
Malaysia - Doctor 23 – 24 Feb 24
Malaysia -Midwives 16 – 17 Mar 29
Laos 30 – 31 Mar 29
Malaysia -Doctors 27 – 28 Apr 20
Mongolia 19 – 22May 23
Cambodia 8 -9 June 20
Malaysia-Midwives 15 – 16 June 28
Vietnam 29 – 30 June 35
TOTAL  222
2.  Up scaling of regional courses
Laos, Cambodia and Mongolia are capable of conducting ICOE themselves 
with minimal supervision. The overseas trainers are competent and OGSM 
needs to only send minimum trainers to oversee the quality. They still face 
challenges in seeking funding to conduct the course as well as funding to 
purchase equipment.  Laos is the best example of up scaling where they are 
gradually purchasing equipment and the success there is clearly from good 
leadership. Cambodia is the least successful in funding and we may have to 
relook at the MOU on whether to continue.
3. ICOE Handbook. 
The book has sold 1820 copies both in Malaysia and overseas and the 3rd 
reprint for another 1000 copies is in progress. There is a strong interest from 
China for the handbook and the Mandarin translation is in the final stages. 
Discussions are continuing with the Laerdal China who is undertaking this 
project on protecting the copyright and royalty of the handbook
4. AOFOG 
AOFOG continues to support and endorse the ICOE in Nepal, Laos, Cambodia 
and Mongolia. The senior officers actively engage with overseas ICOE by 
being present at the courses and the OGSM is grateful for this genuine 
commitment. There is a good likelihood this endorsement for regional work 
will continue for another 2 years until 2021 which is a testimony on the 
consistent quality of the course.
5. Laerdal China 
Laerdal China has observed ICOE in Kuala Lumpur and they are very keen to 
roll out the ICOE in China. Discussions are ongoing and strategies are being 
discussed on the module, funding, copyright and proceeds from the sale 
of the handbook. This will be an important project if it takes off and the 
demand on the trainers will be even more challenging. 
6. Japan 
ICOE was invited to conduct a pre-congress workshop on Complicated 
Caesarean in Nagoya during the annual O&G Congress. This is the second 
time we are invited with funding taken care of by the Japanese organization.
7. China 
ICOE was invited to conduct a workshop on PPH and Complicated Caesarean 
during the annual Medical Simulation Congress in GuangXou. A total of 38 
participants attended this hands on course conducted with our trainers who 
were fluent in Mandarin.
Menopause
Sub-Division
Report
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Our term in office ends in a few days and it is therefore the 
perfect opportunity to ponder on what we have accomplished, 
what is still a ‘work-in-progress’ and perhaps consider the 
‘missed opportunities’ as well. We are indeed fortunate that 
the term has progressed well, as we had from the onset, 
decided on the two key areas of focus for the year. 
The first, was to facilitate the further growth and development 
of the various subcommittees. We therefore began the term 
by appointing new chairpersons to several committees and 
reappointing incumbents to the others. We then met with 
several of them individually to discuss their roles and the 
manner council could assist them in their endeavors.
The ‘Out-patient Gynaecology’ subcommittee was revamped 
and aptly rebranded ‘EPOG’, thereby reflecting the reality 
that this was the committee that would engage with the 
vast majority of the fraternity. Similarly, the trainee program 
was thoroughly reassessed and a consensus on their rightful 
objective reached. The new program was renamed PACT and 
from the very onset took off like a rocket! Most of the other 
subcommittees also raised their game, most notably being the 
Menopause and Medico-legal subcommittees. Certainly, the 
iCOE team persisted with their extremely hectic pace while 
the other subcommittees were kept busy in the usual manner. 
Suffice to say, it has been an incredibly busy year.
The second area of focus was to ‘engage’ with the membership. 
This was a somewhat more multifarious task due to our large 
numbers, diverse outlooks and disparate perceptions. The 
reengineered newsletter was well accepted. The sheer number 
of articles being submitted is a testament to this reality. 
We did however encounter specific difficulties, some 
anticipated, others perhaps not. Fortunately, we were able 
to negotiate these impediments without much collateral 
damage. We would like to believe that we have fulfilled our 
‘caretaker’ role satisfactorily and perhaps helped set some 
new benchmarks.
Finally, in parting, I believe that we must actively identify 
fittingly motivated and talented young members to energize 
our agenda. To enable this, we must reach out to them through 
the innumerable programs that we oversee. Only then can we 
aspire to reinvigorate the Society and allow it to truly achieve 
its full potential. 
 
21
Part 2 Simulated Course
The Part 2 simulated exams were held on the weekend of 
15-16 June. In response to the feedback from participants 
from the previous course, we extended the course to two 
days. It allowed for better discussion as both the trainers 
and participants were not exhausted. Overall, the course 
was well received. Special thanks goes out to Dr Ashley 
Chung Soo Bee and her team for coordinating the course 
and forming all original questions for the course. Look out 
for our next PACT endeavour, the trainee update in ‘Labour 
Ward Management’ which will be held on 6 July 2019
Report On
“OGSM Research Workshop 1: 
Road To Successful Publications 
In Obstetrics & Gynaecology”
By Assoc Prof Dr Ani Amelia Dato Zainuddin
Venue: Makmal Terabyte, Dome 1&2, UKM Medical Centre, 
Cheras, Kuala Lumpur
Date: 2nd March 2019
This research workshop series is the start of a collaboration 
between OGSM and the Dept. of O&G, UKMMC, to create a 
series of workshops that can provide guidance to the O&G 
fraternity; especially the young ones who are interested in 
conducting research and publishing their study results or 
case reports of their clinical work. Publishing is not only 
relevant to academics but also to clinicians as it is evidence 
of their continuing professional development. They can 
share experiences with others in the field which will help 
those facing  similar clinical situations. Publishing improves 
a doctor’s reputation in practice and can widen his/her 
network.   
Since this is the first time such a workshop has been 
conducted, we decided to test the waters by focusing on 
how the O&G fraternity can publish as many completed 
studies and interesting clinical cases which have not yet 
been published. The workshop was conducted in a relatively 
new computer lab in the Preclinical Block of UKM Medical 
Centre. Each participant had his/her own desktop to work 
on their manuscripts during the sessions. 
The lecture topics ranged from an overview to publishing to 
how to conduct literature search and review, how to report 
different types of work, how to report statistical results, 
how to write case reports and even qualitative studies. 
These talks were given by experienced lecturers who had 
extensively published various works. They are experts in 
their respective fields and from different areas of Medicine. 
Dr Ixora also went over common mistakes made in writing 
to guide participants to avoid such issues and to ensure 
successful publications. The afternoon session was a review 
of several manuscripts prepared by participants to help 
improve them before submitting to their chosen journals. 
The first research workshop was a success; the participants 
included were not only O&G trainees, but also sonographers 
and experienced consultants. Everyone who participated 
had a great learning experience. We look forward to the 
second research workshop which will focus on “Writing an 
Impactful Proposal” planned to be held on the 29th of June 
at the same venue.  
Dr Eeson Sinthamoney
And 
finally....

